Delivery Room CPAP in Extremely Low Birth Weight Infants

NCT01223274 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2017-09-26

No results posted yet for this study

Summary

This pilot study was designed to determine the feasibility of randomizing extremely low birth weight (ELBW) infants \<28 weeks' gestation who required resuscitation to one of two resuscitation methods, either: (a) 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV (the intervention group); or (b) 100% oxygen and no CPAP and no PEEP if the infant required PPV (the control group).

Conditions

  • Infant, Newborn
  • Infant, Low Birth Weight
  • Infant, Small for Gestational Age
  • Infant, Premature
  • Bronchopulmonary Dysplasia
  • Continuous Positive Airway Pressure

Interventions

DEVICE

CPAP/PEEP

Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.

DEVICE

Standard management practices

Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH
  • NICHD Neonatal Research Network

    lead NETWORK

Principal Investigators

  • Neil N. Finer, MD · University of California, San Diego

  • Avroy A. Fanaroff, MD · Case Western Reserve University, Rainbow Babies & Children's Hospital

  • Waldemar A. Carlo, MD · University of Alabama at Birmingham

  • Edward F. Donovan, MD · Children's Hospital Medical Center, Cincinnati

  • Charles R. Bauer, MD · University of Miami

  • W. Kenneth Poole, PhD · RTI International

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
10 Minutes
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2003-01-31
Completion
2003-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01223274 on ClinicalTrials.gov